← The Crash Report
The Gap

The Kia Forte Failed Two IIHS Crash Tests. FARS Says It's the Safest Compact Sedan in America.

A Kia Forte sedan in a crash test facility with IIHS measurement markers and a data overlay showing contradicting safety results

IIHS gave the Kia Forte a Poor in its updated moderate overlap front test and another Poor in the updated side impact, making it one of the worst-performing compact sedans by current lab grading criteria.[1][3] If you stopped reading there, you would never buy one.

Now load FARS. Across 2014 to 2023, the Forte recorded 604 fatalities at a rate of 0.40 deaths per 100 million vehicle miles traveled, the lowest of any compact sedan in the database.[2] Lower than the Impreza at 0.52, the Elantra at 1.50, the Corolla at 1.85, and far below the Honda Civic at 2.25 or Ford Focus at 2.52.

5.6×
Death rate gap between the Honda Civic (2.25) and the Kia Forte (0.40) per 100M VMT

A 5.6-times death rate gap between the Civic and the Forte is not a rounding error, and driver behavior cannot explain it. FARS toxicology shows impairment rates across compact sedans clustering within a tight two-percentage-point band: Forte 20.1%, Civic 20.4%, Corolla 19.2%, Focus 19.4%.[2] Compact sedan buyers crash at virtually identical impairment rates regardless of badge, yet the vehicles convert those identical inputs into fatality rates that vary by a factor of six.

So why does the car with the lowest real-world death rate fail a crash test designed to measure exactly that?

Because lab tests and death tolls measure different things on different timelines. IIHS introduced those updated protocols in 2022 and 2023 to catch rear-seat protection gaps that earlier geometries missed; the Forte's front-seat protection scored Good, while its rear passenger head and neck measures scored Poor because inadequate restraint kinematics let the dummy's skull whip into the B-pillar trim.[1] Those failure modes are real but narrow, too new for FARS to register, and represent a small fraction of real-world crash scenarios.

Fleet age explains the rest, and probably more than any engineering variable. Every Kia Forte on American roads rolled off the line between 2010 and 2024, meaning all shipped with ESC, side curtain airbags, and a crash structure designed in the post-small-overlap era. Compare that with the Civic or Corolla, whose FARS tallies reach back to models built before ESC was federally required, and the 5.6× gap looks less like Kia engineering genius and more like fleet arithmetic.

Its successor, the 2025 K4, earned another Poor in the updated moderate overlap for the same rear-passenger weakness.[4] Kia has not fixed the structural compromise, but the K4's real-world death rate will likely stay competitive because every unit carries modern safety hardware and accumulates no generational dead weight in the denominator.

If you are cross-shopping compacts on a budget, the Forte paradox is worth remembering: the newest platform generation almost always wins on real-world survival regardless of brand prestige, because fleet age is the strongest predictor of aggregate death rates in FARS. Lab scores forecast where engineering is going, death rates record where the fleet has been, and for the Forte those two indicators point in opposite directions because they measure different decades of the same car's life.

Sources & References

  1. IIHS, 2024 Kia Forte 4-door sedan, updated moderate overlap front test (Poor) and original moderate overlap front test (Good). iihs.org
  2. NHTSA, Fatality Analysis Reporting System (FARS), 2014–2023. Death rates estimated per 100M VMT using registration-based fleet size and NHTS travel survey mileage. nhtsa.gov
  3. IIHS, 2024 Kia Forte 4-door sedan, updated side impact test (Poor). iihs.org
  4. IIHS, 2025 Kia K4 LXS 4-door, updated moderate overlap front test (Poor), rear passenger restraints and dummy kinematics rated Poor. iihs.org

Data Note: FARS captures only fatal crashes; vehicles with low fatality rates may still carry elevated injury rates not reflected here. VMT estimates introduce approximately ±15% uncertainty for moderate-volume models. Impairment percentages reflect FARS toxicology results for drivers in fatal crashes, not the general driving population. IIHS updated test protocols were introduced in 2022–2023; their effect on real-world outcomes requires several additional years of FARS data to assess. See methodology for caveats.